Day One Biopharmaceuticals, Inc. (DAWN) Stock Overview
Explore Day One Biopharmaceuticals, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Day One Biopharmaceuticals, Inc. (DAWN)
Key Financials
Key Financials
Market Cap
2.2B
P/E Ratio
-20.70
EPS (TTM)
$-1.04
ROE
-0.23%
DAWN Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Day One Biopharmaceuticals, Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of DAWN on the NASDAQ shows an RSI of 0.00, suggesting the stock is in a an oversold condition. Our forecasting models predict a 12-month price target of $8.26 for the NASDAQ listing.
Key metrics behind Day One Biopharmaceuticals, Inc.'s NASDAQ-traded stock include a P/E ratio of -20.70 and a market capitalization of 2.2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of DAWN on the NASDAQ.